Natural regulator may slow several cancers by shutting down fibroblasts, study finds

by CIC bioGUNE

edited by Gaby Clark, reviewed by Andrew Zinin

Gaby Clark

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add as preferred source

An international research team co-led by the Institute of Biomedicine and Biotechnology of Cantabria (IBBTEC-CSIC-University of Cantabria) and CIC bioGUNE, member of BRTA, has identified a novel molecular mechanism that helps limit the progression of several types of cancer.

The findings, published in Nature Communications, reveal that the protein ASPA acts as a natural regulator that prevents the activation of cancer-associated fibroblasts (CAFs), cells within the tumor microenvironment that play a critical role in tumor growth, tissue invasion and metastasis.

The discovery provides new evidence of the importance of the tumor microenvironment, the complex cellular ecosystem surrounding cancer cells, which directly influences disease progression. Understanding how cancer reprograms the healthy cells in surrounding tissue has become one of the main priorities in oncology research, as these interactions can determine tumor aggressiveness and response to treatment.

Looking beyond cancer cells

Although cancer is commonly associated with the uncontrolled proliferation of malignant cells, tumors are composed of a wide variety of interacting cell types. These include immune cells, blood vessels and fibroblasts, which are responsible for maintaining the normal structure and function of tissues.

During tumor development, however, many of these cells are reprogrammed by the tumor itself and begin to support its growth. Among them, CAFs are now recognized as one of the most influential components of the tumor microenvironment because of their ability to promote tumor progression, facilitate cancer cell dissemination and contribute to resistance to certain therapies.

Understanding how this transformation occurs has become a major priority in cancer research and has driven some of the most significant advances in oncology over recent decades, including immunotherapy.

ASPA acts as a natural brake

Against this background, the research team identified ASPA as a key regulator of the behavior of cancer-associated fibroblasts.

The results show that, as tumors progress, a complex interplay between cancer cells and the surrounding healthy tissue leads to a gradual reduction in ASPA expression. As ASPA levels decline, fibroblasts lose an important natural regulatory mechanism and acquire characteristics that promote tumor growth and the development of more aggressive forms of the disease.

The study further demonstrates that ASPA exerts this regulatory function by suppressing TGFβ signaling, one of the principal pathways responsible for activating cancer-associated fibroblasts.

Using a multidisciplinary approach combining biochemical analyses, cellular models, in vivo studies, and advanced single-cell sequencing technologies, the researchers were able to characterize the role of ASPA across multiple tumor types with high precision.

Potential clinical relevance

One of the study's most significant findings is that the loss of ASPA is associated with more aggressive disease progression across different types of cancer. These results suggest that ASPA could potentially serve as a biomarker to identify patients at greater risk of tumor progression and metastasis.

Although this is a fundamental research study with no immediate clinical application, the findings open new opportunities to investigate ASPA as a potential therapeutic target and to develop improved strategies for cancer diagnosis and treatment.

The study was made possible through extensive international collaboration and the generosity of patients who donated essential biological samples for the research.

Publication details

Ianire Astobiza et al, Fibroblastic aspartoacylase suppresses TGFβ-mediated responses and cancer progression, Nature Communications (2026). DOI: 10.1038/s41467-026-73002-6

Journal information: Nature Communications

Key medical concepts

Cancer-Associated FibroblastsTumor MicroenvironmentBiomarkers

Clinical categories

Oncology Provided by CIC bioGUNE Who's behind this story?

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Natural regulator may slow several cancers by shutting down fibroblasts, study finds (2026, July 6) retrieved 6 July 2026 from https://medicalxpress.com/news/2026-07-natural-cancers-fibroblasts.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.